RESUMO
CONTEXTO E OBJETIVO: O angioedema hereditário (AEH) com deficiência de inibidor de C1 manifesta-se por episódios recorrentes de edema envolvendo pele, trato respiratório superior e gastrointestinal. Pode ser letal por asfixia. O objetivo foi avaliar a resposta à terapia dos ataques com icatibanto, inibidor do receptor de bradicinina, recentemente introduzido no Brasil. 
OBJECTIVE
The aim of this study was to describe the clinical response of HAE patients to therapy for HAE attacks using icatibant, an inhibitor of the bradykinin receptor, and the possible side effects. This was the first report on the use of this new drug in a real-life setting.
METHODS
We conducted a prospective experimental single-cohort study on 20 patients who were treated using icatibant. In order to be eligi- The physicians and the patients were asked to describe the symptoms at each site affected (extremities, throat, abdomen, face and external genitalia). Symptom severity was assessed continuously until the subject reported achieving relief. The patients were allowed to leave the hospital facilities after improvement, but were subsequently contacted to confirm that complete resolution of symptoms had occurred. Safety was evaluated by assessing adverse events, changes in physical findings and vital signs before and after the injection. 
RESULTS

From
DISCUSSION
In this study, we reported on treatment using icatibant dur- Importantly, total regression of the complaints occurred within 24 hours (median), in comparison with attacks in which there was no specific drug therapy, which lasted three to five days, as previously reported. 8, 9 Evaluation of icatibant was performed in three controlled trials: FAST-1, FAST-2 and FAST-3. In the FAST-1 trial, statistical significance between the drug and placebo regarding the time taken to achieve symptom relief was not found, although the patients receiving icatibant reported the first endpoint improvement after 2.5 hours and those with the placebo, after 4.6 hours.
The analysis parameters used in this trial and the time taken for the treatment to be introduced probably influenced the results. 8, 10 In the second study, the efficacy of icatibant was compared with tranexamic acid and a significant reduction in symptoms was observed (2.0 hours versus 12.0 hours). FAST-3, which was a ran- In our series of patients, the upper airway obstruction symptoms were the first to resolve. Greve at al. found the same results after reporting on administration of icatibant in 141 attacks in a single patient. 11 During the FAST studies, most of the laryngeal attacks were treated as an open-label phase and the median time taken to achieve relief was longer than one hour. 8, 10 The discrepancy between the findings from those studies and our results may be due to the different analysis parameters used in those studies. The quick response may have been associated with anatomical issues in the upper airways, in which even a small amount of edema can lead to significant clinical repercussions. Also, this observation points to the importance of mediation of this symptom through bradykinin binding to B2 receptors, which is a leading cause of death in HAE patients.
Icatibant is approved in Brazil for use under medical supervision only, i.e. patients are not allowed to inject themselves.
This resulted in a delay in the therapy with a median elapsed time of 6 hours until application, and a maximum of 12 hours.
However, this did not influence the efficacy of the therapy, since our patients who received therapy more than 10 hours after the attack started achieved improvement within the same length of time as shown by those who had early access to medical assistance, as has previously been reported. 12 Development of home treatment strategies for patients with HAE is an important step towards improving the management of this debilitating condition, which would lead to a better response and, consequently, better quality of life. 12, 13 Approval for self-administration is under analysis by the Brazilian authorities.
The attack was classified as severe in approximately 60% of the patients studied (14/24), and suggestive clinical manifestations associated with laryngeal edema were the indication for icatibant use in 50% of the situations in our report. The patients reported that voice changes and facial edema were the sensations that preceded airway obstruction. Although no official classification of severity is available, the Brazilian guidelines was used for therapy indication. 1 Therefore, the severity of the disease may explain some of the delays in achieving complete improvement that were seen in some individuals in this subgroup of patients.
However, patients could choose to have even mild attacks of HAE treated, if the therapy was available. In addition, combination of preventive and on-demand therapy with reduction of the androgen dose and treatment of breakthrough attacks using C1 inhibitor or icatibant has been proposed. 14, 15 Such observations are limited by the type of study developed, with no control group.
Two patients who received icatibant more than once did not observe any reduction in the efficacy of the therapy and did not present any increase in adverse events. Greve et al.
reported that icatibant was used 141 times in one patient without any loss of efficacy. 11 There were no adverse events in one third of our cases and the complaints reported consisted of local burning, hyperemia and mild itching. These symptoms were self-limited and related to local release of histamine induced by subcutaneous injection of icatibant, a development that may be attenuated by H1-antihistamines. 16 Sixty percent (12/20) Most of the patients (65%) reported their first symptoms when they were five years old; only four of them presented after adolescence. The median age for diagnosis was 23 years, thus suggesting that there is a delay in identifying HAE patients.
One patient was 55 years old by the time that the disease was recognized, but its symptoms first presented when she was 15 years old; her case is a testament to how restricted knowledge about HAE is. If we consider the fact that there is almost no registration of cases in other Latin American countries, it becomes obvious that many opportunities to treat HAE patients have been lost. Gastrointestinal complaints were reported by 62.5% of our patients and were not associated with facial edema in 21% of the cases treated in our experience.
Marqués et al. reported that one potential future use for icatibant would be for short-term prophylactic HAE treatment, and they reported on its use for a patient with previous severe attacks during some procedures. 19 The patients who may benefit from switching to on-demand therapy, or from combining preventive and on-demand therapy, include women, children and adolescents, as well as patients with various risk factors for androgens such as organ toxicity, cardiovascular disease or possible drug interactions. 20 Use of icatibant has been restricted for patients under 18 years of age and for patients with cardiac diseases.
Medication cost is a major concern for both patients and physicians. The US Hereditary Angioedema Association has estimated that hospital stays and emergency department visits during acute attacks comprise 68% of the cost of a severe attack. 22 As understanding of HAE physiopathology and management improves, decisions regarding continuous or on-demand therapy should become easier, and studies evaluating pharmacoeconomics will certainly help.
CONCLUSIONS
The HAE type I patients who received icatibant responded promptly; most of them achieved improved symptom severity within 30 minutes. Mild local adverse events were reported in 75% of the patients. The introduction of this new drug has opened up new perspectives for HAE patients regarding therapies for attacks.
